THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (Nasdaq:RPRX) and (PCX:RPRX) today released preliminary three-month findings from its current six-month European study of Proellex™ in the treatment of endometriosis. The study included three dose levels of Proellex™ as well as a positive control arm. The positive control was Leuprolide Injection (Lucrin®), a GnRH agonist also known as Lupron®, commonly used for the treatment of endometriosis. Proellex will be administered for six months as a daily oral dose of 12.5mg, 25mg, or 50mg capsules.
